SRF-617
- Generic Name
- SRF-617
Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer
Phase 2
Terminated
- Conditions
- Prostate CancerMetastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Coherus Biosciences, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT05177770
- Locations
- 🇺🇸
START South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States
🇺🇸START Mountain Region, Utah Cancer Specialists, West Valley City, Utah, United States
🇨🇦BC Cancer - The Vancouver Centre, Vancouver, British Columbia, Canada
Study of SRF617 in Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Advanced Solid Tumor
- Interventions
- First Posted Date
- 2020-04-07
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Coherus Biosciences, Inc.
- Target Recruit Count
- 85
- Registration Number
- NCT04336098
- Locations
- 🇺🇸
University of Washington, Seattle, Washington, United States
🇺🇸The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸City of Hope, Duarte, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath